β Scribed by Robert Langer; Marsha Moses
No coin nor oath required. For personal study only.
The development of biocompatible, controlled release systems for macromolecules has provided the opportunity for researchers and clinicians to target and deliver, on site, biologically active factors. This advance has also facilitated the purification and characterization of a number of important biomolecules. These systems include controlled release delivery systems which release proteins through porous polymer matrices, degradable polymeric delivery systems, and modulated polymer release systems. These areas of research will be reviewed with regards to their design, release kinetics, and biocompatibilities. The utilization of these systems to release such biologically important polypeptides as growth factors (e.g., fibroblast growth factor, epidermal growth factor, transforming growth factorβB) as well as a number of important inhibitory factors (e.g., nitrosoureas, angiogenesis inhibitors) in both in vivo and in vitro studies will be discussed.
π SIMILAR VOLUMES
## Abstract A method to incorporate 2,2β²β(or 4,4β²β)dipyridyl and tetraβ__n__βbutylammonium hydroxide into poly(vinyl alcohol) (PVA) monoliths and the controlledβrelease properties of these polymer monoliths for delivery of the reagents are reported. The monoliths were prepared by heating PVA beads
Recombinant human transforming growth factor β€1 (TGF-β€1) was incorporated into biodegradable microparticles of blends of poly(DL-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) at 6 ng/1 mg microparticles. Fluorescein isothiocynate labeled bovine serum albumin (FITC-BSA) was coencaps
## Abstract Plateletβrich plasma (PRP) represents an autologous source of growth factors essential for bone regeneration. The clinical efficacy of PRP is, however, unpredictable, and this is likely due to the inefficient and inconsistent delivery of PRPβderived growth factors. Previous investigatio